VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-19.24%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$117M
AUM Growth
+$117M
(-50%)
Cap. Flow
-$57.9M
Cap. Flow
% of AUM
-49.3%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
5
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$24.5M |
| 2 |
Akero Therapeutics
AKRO
|
$16.8M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$13.4M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$1.72M |
| 5 |
Precision BioSciences
DTIL
|
$1.55M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Akero Therapeutics
AKRO
$3.74B
| $66.8M | 56.91% | 3,150,019 -790,524 | -20% | -$16.8M |
|
|
2
Precision BioSciences
DTIL
$57.8M
| $24.2M | 20.6% | 4,007,901 -257,240 | -6% | -$1.55M |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $13.4M | 11.45% | 501,584 -498,416 | -50% | -$13.4M |
|
|
TPTX
4
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $7.16M | 6.1% | 160,333 -547,900 | -77% | -$24.5M |
|
5
VYNE Therapeutics
VYNE
$8.16M
| $3.92M | 3.34% | 1,461,552 | – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $1.88M | 1.6% | 456,770 -418,230 | -48% | -$1.72M |
|